Search Results
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Application (BLA) for PVEK was recently submitted to the FDA seeking approval for patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare blood cancer.6 Details on key presentations at the ASH 2025 Congress are available below and the full abstracts
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for ITVISMA® (onasemnogene abeparvovec-brve)
care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including
More news about: Orsini
Dec 02, 2025, 08:00 ET Cresset Expands Presence in Houston, Welcomes Advisory Team with $1.4 Billion in AUM
Ellington. "Cresset's vision to build a 100+-year firm resonates deeply with us, as does the alignment between employees, leadership, and clients. That is rare in this industry, and it is why we are so excited for what the future holds."About Cresset
More news about: Cresset
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
anthracycline-based chemotherapy in lymphoma. Among 1,414 patients treated with CHOP- or ABVD-based regimens across eight U.S. centers, extravasation was rare in both groups, with only one documented case in the CVC cohort and two suspected cases in the PIV cohort. No significant differences were observed
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 02, 2025, 07:09 ET American Liver Foundation Hosts the 34th Annual Irwin M. Arias Symposium
Jennifer Lippincott-Schwartz, PhD – Howard Hughes Medical Institute How a Partnership of Patients, Researchers and Clinicians can Defeat Even Rare Cancers, Lessons from Fibrolamellar Carcinoma Sanford M. Simon, PhD, Rockefeller University Quo Vadis,
More news about: American Liver Foundation
Dec 02, 2025, 07:07 ET Amid superlative IB results, Washington International School advances next-gen learning with its new 58,000 sq. ft. center -- and much more
here.WIS also is marking another year of an outstanding IB DP Diploma award rate of 94% and an IB Bilingual Diploma award rate that's rare in our region, in the USA, and across the world, at 71%. This clocks on the upper side of WIS's own five-year average, and
More news about: Washington International School
Dec 02, 2025, 07:00 ET U.S. FDA GRANTS BIRCHBIOMED ORPHAN DRUG DESIGNATION FOR FS2 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
compounds intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders such as IPF, that affect fewer than 200,000 people in the U.S. Idiopathic pulmonary fibrosis (IPF), a rare and serious chronic lung disease, results in scarring (fibrosis) of the lungs for an
More news about: BirchBioMed Inc
Dec 02, 2025, 07:00 ET VinFast VF 9 - Your Home, Wherever the Road Takes You
traditionally offered that rare quiet: A moving refuge, a small private room where the world outside fades away. Today, electric vehicles are beginning to deliver that same sense of peace, but with a cleaner conscience and a more affordable price tag.One of those rare offerings is the VF 9, a seven‑seat
More news about: Vinfast Auto LLC
Dec 02, 2025, 07:00 ET AISA Pharma Announces Completion of Enrollment in Phase 2 RECONNOITER Trial of AISA-021 in Systemic Sclerosis-Related Raynaud's Phenomenon
randomized crossover study. Aisa is developing AISA-021 for the treatment of Raynaud's in Systemic Sclerosis (SSc), and Systemic Sclerosis itself, which is a rare disease affecting 100,000 Americans with the highest mortality of any autoimmune disease.
More news about: Aisa Pharma
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
The pharmaceutical industry's commitment to addressing complex and rare diseases, coupled with advancements in genomics and biologics, is fueling this robust market expansion. Top-tier decision-makers, including CEOs, Managers,
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 05:00 ET Global Wellness Awards Spotlight Leaders Transforming the World's $6.8 Trillion Wellness Economy
in the Science of Wellness: Deepak Srivastava, MDThe Bennett Family Award for Collaboration in the Science of Wellness honors those rare leaders who understand that the greatest discoveries are not achieved alone—but through partnership, curiosity, and the relentless pursuit of shared
More news about: Global Wellness Summit
Dec 02, 2025, 02:27 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
conventional anti-seizure medications2Eight presentations at AES highlight Lundbeck's dedication to improving outcomes for people with rare epilepsiesVALBY, Denmark, Dec. 2, 2025 /PRNewswire/ -- H. Lundbeck
More news about: H. Lundbeck A/S
Dec 02, 2025, 02:25 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
conventional anti-seizure medications2Eight presentations at AES highlight Lundbeck's dedication to improving outcomes for people with rare epilepsiesVALBY, Denmark, Dec. 2, 2025 /PRNewswire/ -- H. Lundbeck
More news about: H. Lundbeck A/S
Dec 02, 2025, 00:00 ET GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit
More news about: GC Biopharma
Dec 01, 2025, 21:51 ET DIGITIMES ASIA: AI workload surge creates opening for alternative memory and chiplet technologies, expert says
artificial intelligence (AI) workloads is forcing a fundamental redesign of data center infrastructure, driving historic memory shortages and opening a rare market window for alternative memory technologies, according to Chuck Sobey, founder of ChannelScience and general chair of the Chiplet Summit.
More news about: DIGITIMES
Dec 01, 2025, 19:35 ET Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
[email protected]*DIAD: Dominantly Inherited Alzheimer's disease (DIAD) is a rare form of AD that causes memory loss and dementia in individuals — typically while they are in their 30s to 50s. The disease affects less than 1% of the
More news about: Eisai Inc.
Dec 01, 2025, 17:54 ET Life Sciences Innovators Convene at BioFlorida's 28th Annual Innovation Conference
is unmistakable, and this conference made that clear," said Mark Glickman, President and CEO of BioFlorida. "With 80 speakers spanning AI innovation, rare disease breakthroughs, and global partnerships, the 28th Annual Innovation Conference captured the breadth of Florida's capabilities. BioFlorida's
More news about: BioFlorida
Dec 01, 2025, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class
More news about: PTC Therapeutics, Inc.
Dec 01, 2025, 16:06 ET Genetic Research Pinpoints a Lethal Risk Linked to Adams-Oliver Syndrome
Dec. 1, 2025 /PRNewswire/ -- Scientists at Cincinnati Children's have taken a key early step in understanding why some people born with the rare disease Adams-Oliver syndrome (AOS) experience potentially fatal disruptions in heart and vascular development.
More news about: Cincinnati Children's Hospital Medical Center
Dec 01, 2025, 15:16 ET The Patina Collective & Artist Jesse Draxler Debut "The Machine of Loving Grace"
installation constructs a hybrid environment—part sanctuary, part industrial apparatus—using LED walls, moving-image projection, photographic works, rare vehicles, and collected ephemera. Within this expanded framework, the work examines the phenomenology of travel: the drift of highway time, the dissolution
More news about: The Patina Collective
Dec 01, 2025, 14:45 ET The Melvin Family (of NBC's Craig Melvin) Launches Hand Made Candle Company Melvin Made Benefitting Cancer Charities
/PRNewswire/ -- NBC News' Craig Melvin's family is turning the tragedies of losing his brother, Lawrence to colorectal cancer and young niece, Jasmine to a rare pediatric cancer into giving back. The family is starting a new candle company, Melvin Made. The company will launch on Giving Tuesday (December
More news about: Craig Melvin
Dec 01, 2025, 13:08 ET Célébrant ses 100 ans, Duas Rodas dévoile sa nouvelle marque DR Flavors & Ingredients et entame un nouveau cycle d'évolution.
».Rosemeri Francener renforce le sentiment de responsabilité qui accompagne ce nouveau cycle. « Atteindre 100 ans d'existence est un exploit rare. Mais plus que cela, c'est une responsabilité. Nous honorons notre histoire en continuant à nous développer en nous concentrant sur nos objectifs et
More news about: Duas Rodas
Dec 01, 2025, 12:47 ET Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
ideal candidates for deeply personalized treatment plans. This capability gives biologics a significant advantage in oncology, autoimmune diseases, rare diseases, and metabolic disorders where precision is essential. The growing availability of genomic data, expanded research in immunology, and patient
More news about: Strategic Revenue Insights
Dec 01, 2025, 12:25 ET Zen Technologies USA Unveils its Next-Generation AI-Enabled Live and Virtual Simulation Training Capabilities at I/ITSEC 2025
Commenting on the launch, Ashok Atluri, Chairman & Managing Director, Zen Technologies Limited, said, "Zen brings something rare to I/ITSEC 2025 - training systems that have been refined through actual operational use, not just lab testing. Our simulators are deployed with allied
More news about: Zen Technologies USA
Dec 01, 2025, 12:00 ET Three Honored with AESC Lifetime Achievement Award
philosophy, entrepreneurial spirit, and unwavering integrity have elevated the standards of our profession globally."Marcus Herold's career is a rare example of consistency, foresight, and purpose. Over five decades, he has built MPS Enterprises Ltd., a member of Panorama, into one of the most respected
More news about: Association of Executive Search and Leadership Consultants